SwedenBIOs USA-orienterade arbete
Årets JP Morgan ställde om till digitalt möte i sista stund men många aktörer som planerat att delta fysiskt var ändå på plats, så även en mindre delegation bestående av Business Sweden, Business Region Göteborg och SwedenBIO.
Expert insights for Swedish life science companies eyeing U.S. growth.
The Swedish American Chamber of Commerce of San Francisco has recently appointed SwedenBIOs CEO Helena Strigård to take part in their advisory board, where she will join leading representatives of Swedish and Californian industry and academia.
Nordic life science startups looking to expand into the U.S. market are invited to a unique opportunity hosted by the U.S. Department of Commerce and SelectUSA.
As a part of the new set of collaborations between Swedish and Californian life science industries, the Swedish American Chamber of Commerce (SACC) in San Diego and SwedenBIO has entered into a memorandum of understanding (MoU), which will enable both organizations to strengthen their support to life science companies.
As a result of the strengthened collaboration between SACC and SwedenBIO, there is now an opportunity to receive a young professional from an American university for a traineeship in Sweden, or to welcome a Swedish young professional for a traineeship in the US.
As a part of the new set of collaborations between Swedish and Californian life science industries, The Swedish American Chamber of Commerce (SACC) in San Diego and SwedenBIO enters into a memorandum of understanding (MoU), which will enable both organizations to strengthen their support to life science companies.
Intresset från svenska noterade bolag att göra en så kallad ”dual listing” i USA har ökat kraftigt. Varje år väljer ca 15 europeiska bolag att notera sig på Nasdaq USA, och de senaste åren har vi sett ett ökat intresse för en Nasdaq USA-notering från Norden. Med Ymab, Orphazyme, Calliditas och nu senast Galecto som exempel. Dessa bolag har valt att notera sig via en traditionell IPO eller en dual listning kombinerad med en kapitalanskaffning riktad mot både amerikanska och nordiska investerare. Överväger ni en USA-notering? I faktabladet får ni värdefulla tips.
In a recent mapping of the Swedish and Californian life science sectors, several common areas of strengths were identified, notably immuno-oncology, rare diseases/orphan drugs and cell and gene therapy. This has spurred a new link forming between these life science hot spots to secure that opportunities for innovative and brilliant minds to join forces in tackling health challenges are not lost.
Brännpunkt Life Science är en intervjuserie i samarbete med DNB Sverige som riktar förstoringsglaset mot skärningspunkten mellan innovation, kapital och hälsa. I första delen möter vi Adam Kostyal, europeisk noteringschef på Nasdaq, som tittar på hur börsåret såg ut för sektorn, pratar om pandemins påverkan och delar med sig av framtidsspaningar.
